Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: recommendations of an expert panel

International Society to Advance Alzheimer's Research and Treatment, Alzheimer's Association; Global Brain Consortium; Claudio Babiloni; Mario Parra-Rodriguez; William J. McGeown

doi:10.1002/alz.12311

Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: recommendations of an expert panel

International Society to Advance Alzheimer's Research and Treatment, Alzheimer's Association, Global Brain Consortium, Claudio Babiloni, Mario Parra-Rodriguez, William J. McGeown

Psychology

Research output: Contribution to journal › Article › peer-review

104 Citations (Scopus)

67 Downloads (Pure)

Abstract

The Electrophysiology Professional Interest Area (EPIA) and Global Brain Consortium endorsed recommendations on candidate electroencephalography (EEG) measures for Alzheimer's disease (AD) clinical trials. The Panel reviewed the field literature. As most consistent findings, AD patients with mild cognitive impairment and dementia showed abnormalities in peak frequency, power, and “interrelatedness” at posterior alpha (8-12 Hz) and widespread delta (< 4 Hz) and theta (4-8 Hz) rhythms in relation to disease progression and interventions. The following consensus statements were subscribed: (1) Standardization of instructions to patients, resting state EEG (rsEEG) recording methods, and selection of artifact-free rsEEG periods are needed; (2) power density and “interrelatedness” rsEEG measures (e.g., directed transfer function, phase lag index, linear lagged connectivity, etc.) at delta, theta, and alpha frequency bands may be use for stratification of AD patients and monitoring of disease progression and intervention; and (3) international multisectoral initiatives are mandatory for regulatory purposes.

Original language	English
Pages (from-to)	1528-1553
Number of pages	26
Journal	Alzheimer's and Dementia
Volume	17
Issue number	9
Early online date	15 Apr 2021
DOIs	https://doi.org/10.1002/alz.12311
Publication status	Published - 28 Sept 2021

Funding

The present paper was facilitated by the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART), through the electrophysiology professional interest area (PIA). EPIA is committed to (1) exploit EEG biomarkers for improving the understanding of neurophysiological mechanisms underlying Alzheimer's disease and age-related dementing disorders at micro, meso, and macro spatial scale and (2) promoting clinical applications. Of note, the views and opinions expressed by authors in this publication represent those of the authors and do not necessarily reflect those of the PIA membership, ISTAART, or the Alzheimer's Association. Furthermore, this manuscript was facilitated by the Global Brain Consortium (https://globalbrainconsortium.org). The Global Brain Consortium is committed to achieving the vision of improved and more equitable health outcomes worldwide by strengthening linkages between neuroscientists across borders and disciplines. Quantitative EEG techniques and biomarkers are considered an important resource for brain research and clinical applications in neurologic and psychiatric diseases, especially in lower- and middle-income countries.

Keywords

Alzheimer disease
dementia
biomarkers
clinical trials
ectroencephalography (EEG)
eyes-closed resting state condition
The Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART)

Access to Document

10.1002/alz.12311

Babiloni-etal-AAD-2021-Measures-of-resting-state-EEG-rhythms-for-clinicalAccepted author manuscript, 2.71 MB

Cite this

International Society to Advance Alzheimer's Research and Treatment, Alzheimer's Association, Global Brain Consortium, Babiloni, C., Parra-Rodriguez, M., & McGeown, W. J. (2021). Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: recommendations of an expert panel. Alzheimer's and Dementia, 17(9), 1528-1553. https://doi.org/10.1002/alz.12311

@article{fe4539adf44744319202388b1514a322,

title = "Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: recommendations of an expert panel",

abstract = "The Electrophysiology Professional Interest Area (EPIA) and Global Brain Consortium endorsed recommendations on candidate electroencephalography (EEG) measures for Alzheimer's disease (AD) clinical trials. The Panel reviewed the field literature. As most consistent findings, AD patients with mild cognitive impairment and dementia showed abnormalities in peak frequency, power, and “interrelatedness” at posterior alpha (8-12 Hz) and widespread delta (< 4 Hz) and theta (4-8 Hz) rhythms in relation to disease progression and interventions. The following consensus statements were subscribed: (1) Standardization of instructions to patients, resting state EEG (rsEEG) recording methods, and selection of artifact-free rsEEG periods are needed; (2) power density and “interrelatedness” rsEEG measures (e.g., directed transfer function, phase lag index, linear lagged connectivity, etc.) at delta, theta, and alpha frequency bands may be use for stratification of AD patients and monitoring of disease progression and intervention; and (3) international multisectoral initiatives are mandatory for regulatory purposes.",

keywords = "Alzheimer disease, dementia, biomarkers, clinical trials, ectroencephalography (EEG), eyes-closed resting state condition, The Alzheimer{\textquoteright}s Association International Society to Advance Alzheimer{\textquoteright}s Research and Treatment (ISTAART)",

author = "{International Society to Advance Alzheimer's Research and Treatment, Alzheimer's Association} and {Global Brain Consortium} and Claudio Babiloni and Mario Parra-Rodriguez and McGeown, {William J.}",

year = "2021",

month = sep,

day = "28",

doi = "10.1002/alz.12311",

language = "English",

volume = "17",

pages = "1528--1553",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

number = "9",

}

International Society to Advance Alzheimer's Research and Treatment, Alzheimer's Association, Global Brain Consortium, Babiloni, C, Parra-Rodriguez, M & McGeown, WJ 2021, 'Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: recommendations of an expert panel', Alzheimer's and Dementia, vol. 17, no. 9, pp. 1528-1553. https://doi.org/10.1002/alz.12311

Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: recommendations of an expert panel. / International Society to Advance Alzheimer's Research and Treatment, Alzheimer's Association; Global Brain Consortium; Babiloni, Claudio et al.
In: Alzheimer's and Dementia, Vol. 17, No. 9, 28.09.2021, p. 1528-1553.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease

T2 - recommendations of an expert panel

AU - International Society to Advance Alzheimer's Research and Treatment, Alzheimer's Association

AU - Global Brain Consortium

AU - Babiloni, Claudio

AU - Parra-Rodriguez, Mario

AU - McGeown, William J.

PY - 2021/9/28

Y1 - 2021/9/28

N2 - The Electrophysiology Professional Interest Area (EPIA) and Global Brain Consortium endorsed recommendations on candidate electroencephalography (EEG) measures for Alzheimer's disease (AD) clinical trials. The Panel reviewed the field literature. As most consistent findings, AD patients with mild cognitive impairment and dementia showed abnormalities in peak frequency, power, and “interrelatedness” at posterior alpha (8-12 Hz) and widespread delta (< 4 Hz) and theta (4-8 Hz) rhythms in relation to disease progression and interventions. The following consensus statements were subscribed: (1) Standardization of instructions to patients, resting state EEG (rsEEG) recording methods, and selection of artifact-free rsEEG periods are needed; (2) power density and “interrelatedness” rsEEG measures (e.g., directed transfer function, phase lag index, linear lagged connectivity, etc.) at delta, theta, and alpha frequency bands may be use for stratification of AD patients and monitoring of disease progression and intervention; and (3) international multisectoral initiatives are mandatory for regulatory purposes.

AB - The Electrophysiology Professional Interest Area (EPIA) and Global Brain Consortium endorsed recommendations on candidate electroencephalography (EEG) measures for Alzheimer's disease (AD) clinical trials. The Panel reviewed the field literature. As most consistent findings, AD patients with mild cognitive impairment and dementia showed abnormalities in peak frequency, power, and “interrelatedness” at posterior alpha (8-12 Hz) and widespread delta (< 4 Hz) and theta (4-8 Hz) rhythms in relation to disease progression and interventions. The following consensus statements were subscribed: (1) Standardization of instructions to patients, resting state EEG (rsEEG) recording methods, and selection of artifact-free rsEEG periods are needed; (2) power density and “interrelatedness” rsEEG measures (e.g., directed transfer function, phase lag index, linear lagged connectivity, etc.) at delta, theta, and alpha frequency bands may be use for stratification of AD patients and monitoring of disease progression and intervention; and (3) international multisectoral initiatives are mandatory for regulatory purposes.

KW - Alzheimer disease

KW - dementia

KW - biomarkers

KW - clinical trials

KW - ectroencephalography (EEG)

KW - eyes-closed resting state condition

KW - The Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART)

UR - https://alz-journals.onlinelibrary.wiley.com/journal/15525279

U2 - 10.1002/alz.12311

DO - 10.1002/alz.12311

M3 - Article

SN - 1552-5260

VL - 17

SP - 1528

EP - 1553

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 9

ER -

International Society to Advance Alzheimer's Research and Treatment, Alzheimer's Association, Global Brain Consortium, Babiloni C, Parra-Rodriguez M , McGeown WJ. Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: recommendations of an expert panel. Alzheimer's and Dementia. 2021 Sept 28;17(9):1528-1553. Epub 2021 Apr 15. doi: 10.1002/alz.12311

Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: recommendations of an expert panel

Abstract

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this